Revealing the molecular mechanisms of levofloxacin-induced cognitive impairment and epilepsy: an integrated bioinformatics and molecular dynamics simulation

揭示左氧氟沙星诱发认知障碍和癫痫的分子机制:生物信息学和分子动力学综合模拟

阅读:1

Abstract

BACKGROUND: Levofloxacin is a widely used quinolone antibiotic with good antibacterial properties and high oral utilization. Nevertheless, it is associated with adverse reactions affecting central nervous system (CNS), which in severe cases may include cognitive impairment and epilepsy --potentially life-threatening outcomes. And research on factors contributing to these severe adverse reactions remains limited. Therefore, it is of great significance to investigate the molecular mechanisms underlying levofloxacin-induced CNS injury. METHODS: This study investigated the molecular mechanisms underlying levofloxacin-induced CNS injury by integrating bioinformatics, network toxicology, molecular docking and dynamics simulation. Differentially expressed genes were identified from databases like GEO and Genecards, leading to 33 overlapping drug-disease targets. Subsequently, Protein interaction networks and cytoHubba algorithms identified HSP90AA1 as a key target. Its central role was further validated by receiver operating characteristics (ROC) curves and molecular dynamics simulation. Additionally, GSEA analysis revealed that several pathways that are likely involved. RESULTS: This study revealed that levofloxacin may induces CNS injury likely by targeting HSP90AA1 and perturbing key signaling pathways. The key signaling pathways include NOD-like receptor (NLR) signaling pathway, neutrophil extracellular trap (NET) formation, and MAPK signaling pathway. Furthermore, molecular docking revealed a strong binding affinity between levofloxacin and HSP90AA1(-9.9 kcal/mol) and molecular dynamics simulation over 100-ns simulations made further validation. CONCLUSION: These findings indicate that levofloxacin disrupts neuronal homeostasis via HSP90AA1-mediated inflammatory pathways, providing critical implications for optimizing clinical application of levofloxacin and mitigating its CNS-related risks. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40360-025-01025-8.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。